echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sihuan Pharmaceutical "disrupts" 3.5 billion cardiovascular products, Renfu and Dongyang Pharmaceutical, 5 companies report for production

    Sihuan Pharmaceutical "disrupts" 3.5 billion cardiovascular products, Renfu and Dongyang Pharmaceutical, 5 companies report for production

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Sihuan Pharmaceutical issued an announcement stating that Foshan Derek Pharmaceutical (a subsidiary of Pharmadax Inc.


    Data show that Metoprolol is the world's first selective β1 receptor blocker, which can reduce the risk of bronchoconstriction, so it has become a commonly used drug for chronic heart failure


    Sales of terminal metoprolol tablets in public medical institutions in China in recent years (unit: 100 million yuan)

    Source: Mi Nei.


    According to data from Meinenet, the sales growth rate of terminal metoprolol tablets in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has maintained above 10% in the past two years.


    Source: One piece retrieval from Mi Nei.


    The main products of Metoprolol Tablets include Metoprolol Succinate Sustained Release Tablets, Metoprolol Tartrate Tablets, Metoprolol Tartrate Sustained Release Tablets (Ⅱ), etc.


    At present, five companies including Yichang Renfu Pharmaceutical, Zhejiang Prokangyu Pharmaceutical, Guangdong Dongyang Sunshine Pharmaceutical and other metoprolol succinate sustained-release tablets are under review and approval for generic 4 types of production


    Source: Listed company announcements, Mi Nei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.